



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
February 15, 2023**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the “Oversight Committee Board Packet” section for the corresponding meeting date.

Call to Order – Agenda Item 1

Presiding Officer Dr. Mahendra Patel announced a quorum present and called the meeting to order at 9:00 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Mahendra Patel, M.D., P.A.

David Cummings, M.D. (attended by videoconference pursuant to by Tex. Gov’t Code § 551.127)

Donald (Dee) Margo

Ambrosio Hernandez, M.D.

Will Montgomery

Cindy Barberio Payne

Bill Rice, M.D. (attended by videoconference pursuant to by Tex. Gov’t Code § 551.127)

Craig Rosenfeld, M.D.

Presiding Officer Dr. Patel noted for the record that Dr. Cummings and Dr. Rice are participating in the meeting via videoconference.

**Adoption of Minutes from the November 16, 2022, Meeting – Agenda Item 3,
Tab 1**

MOTION:

On a motion by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the minutes of the November 16, 2022, Oversight Committee meeting as presented.

Public Comment – Agenda Item 4

Presiding Officer Dr. Patel noted for the record that no member of the public requested to provide comments.

Chief Executive Officer Report – Agenda Item 5, Tab 2

Presiding Officer Dr. Patel recognized Chief Executive Officer Wayne Roberts to present his report.

Mr. Roberts announced that CPRIT received a donation from Travis County ESD #12. He acknowledged Cassidy Buth, the department's Public Information Officer, who attended the meeting on behalf of Travis County ESD #12.

He reported the amount of grant funds available for the remainder of FY2023 and noted that each of the three programs is fully subscribed for this fiscal year. He also introduced new personnel and notified members that CPRIT has filled 42 FTEs and is in the process of hiring a technical writer and compliance specialist.

Mr. Roberts noted the release of the Fiscal Year 2022 CPRIT Annual Report on January 31. He thanked CPRIT staff for their contributions and recognized Mark Loeffler, Justin Rand, Kristen Doyle, Bridget Barstow, and the CPRIT IT team for their work to write and design the report.

Mr. Roberts informed members that he testified before Senate Finance on January 30 and will appear before the House Appropriations Subcommittee on Articles I, IV, & V on February 21.

He concluded his presentation with the CEO FY 2022 report on the progress and continued merit of each research program, as required by Texas Health and Safety Code § 102.260(c). He referred to his written report behind Tab 2, which provides an overview of the progress made in advancing CPRIT's mission to create and expedite innovation in cancer research and cancer prevention in FY 2022.

Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 6, Tab 3

Presiding Officer Dr. Patel recognized Chief Compliance Officer Vince Burgess to present the Compliance Report and Compliance Certification of Grant Award Process.

Mr. Burgess directed the oversight committee members to tab three of the meeting book and presented the report for the past quarter's compliance activities.

An Oversight Committee member asked how CPRIT addresses repeat findings in the compliance review process. Mr. Burgess explained that the compliance team incorporates repeat findings into the compliance monitoring review process for appropriate follow up.

Following his report, Mr. Burgess presented the Compliance Certification for the proposed academic research grant awards and prevention grant awards, confirming that the proposed awards and review process complied with all applicable state laws and agency requirements.

Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 7, Tab 4

Presiding Officer Dr. Patel recognized Chief Scientific Officer Dr. Le Beau to present the academic research program award recommendations and update.

Dr. Le Beau directed Oversight Committee members to Table 1 on page 4 of the Proposed Grant Awards Book, which displayed the Scientific Review Council (SRC) and Program Integration Committee (PIC) recommendations for the FY2023 review cycle 1 and recruitment cycles 23.2 and 23.3. Dr. Le Beau noted that one recruitment application withdrew from consideration after the PIC meeting. She recommended that the Oversight Committee approve 39 awards and award funding of \$75,134,078 and defer action on IIRA applications recommended by the SRC with overall scores of 2.8 and higher.

Dr. Le Beau provided an overview of the recommended awards.

Recommended Individual Investigator Research Awards (IIRA) FY23.1

Rank	Grant ID	Award	Score	Application Title	PI	Organization	Budget
1	RP230026	IIRA-CCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRA-PED	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GliCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
6	RP230018	IIRA-CCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRA-PED	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

Rank	Grant ID	Award	Score	Application Title	PI	Organization	Budget
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of “Don’t Eat Me” Signals Converts Local Radiotherapy into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore Immune Recognition in Pancreatic Cancer	Viale, Andrea	The University of Texas M. D. Anderson Cancer Center	\$1,049,985
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRA-PED	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRA-CT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRA-CSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

Rank	Grant ID	Award	Score	Application Title	PI	Organization	Budget
21	RP230120	IIRA-CCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas with Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRA-PED	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRA-CSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRA-CSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRA-CCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson Cancer Center	\$1,019,997
29	RP230330	IIRA-CCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997

IIRA – Individual Investigator Research Award

IIRA-CCA – Individual Investigator Research Award for Cancer in Children and Adolescents

IIRA-CT – Individual Investigator Research Award for Clinical Translation

IIRA-CSBC – Individual Investigator Research Award for Computational Systems Biology of Cancer

IIRA-PED – Individual Investigator Research Award for Prevention and Early Detection

Recommended Texas Regional Excellence in Cancer (TREC) Awards FY23.1

Rank	Grant ID	Award	Score	Application Title	PI	PI Organization	Budget
1	RP230419	TREC	2.8	South Texas Center of Excellence in Cancer Research (ST-CECR)	Chauhan, Subhash	The University of Texas Rio Grande Valley	\$6,000,000
2	RP230420	TREC	2.8	Impacting Cancer Outcomes in Hispanics (ICOHN)	Lakshmanaswamy, Rajkumar	Texas Tech University Health Sciences Center at El Paso	\$6,000,000
3	RP230204	TREC	2.8	Gene-Environment: Lifestyle Interactions in Cancer	Ramos, Kenneth	Texas A&M University System Health Science Center	\$5,998,422

Recommended Recruitment Awards FY 2023 Cycle 23.4

Rank	Grant ID	Award	Score	Application Title	Candidate	Organization	Budget
1	RR230012	RFTFM	1	First-Time, Tenure-Track: Dr. Kenneth Hu	Kenneth Hu	UT MD Anderson Cancer Center	\$2,000,000
2	RR230019	RFTFM	1.6	First-Time, Tenure-Track: Dr. Lu Wang	Lu Wang	UT HSC at San Antonio	\$2,000,000
3	RR230020	REI	2.0	Recruitment of Established Investigators, Dr. Hongfang Liu	Hongfang Liu	UT Health Science Center at Houston	\$6,000,000
4	RR230018	REI	2.7	Recruitment of Established Investigators, Dr. Rudi Fasan	Rudi Fasan	University of Texas at Dallas	\$6,000,000
5	RR230015	RFTFM	2.8	First-Time, Tenure-Track: Dr. Ewan McRae	Ewan McRae	The Methodist Hospital Research Institute	\$1,999,977

REI – Recruitment of Established Investigator

RFTFM – Recruitment of First-Time, Tenure Track Faculty Members

In response to a question from an Oversight Committee member inquiring about the funding status of deferred grant applications, Dr. Le Beau explained that CPRIT could fund the deferred applications before September 1, 2023, if money is available.

Compliance Certification

Presiding Officer Dr. Patel reminded members that Mr. Burgess previously certified compliance of the academic research awards process.

Conflict of Interest Notification

Presiding Officer Dr. Patel noted for the record that Dr. Rosenfeld reported a conflict of interest with one academic research application recommended for an award, grant ID number RP230344.

Approval Process – Academic Research Awards

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Hernandez, the Oversight Committee members present and able to vote unanimously approved the PIC's recommendation for an Individual Investigator Research Award for grant application number RP230344.

Presiding Officer Dr. Patel noted for the record that Dr. Rosenfeld did not vote.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the PIC's recommendations for the eight mechanisms: Recruitment of First-Time, Tenure-Track Faculty Members; Recruitment of Established Investigators; the Texas Regional Excellence in Cancer; and Individual Investigator Research Awards, including those specifically awarded for Childhood and Adolescent Cancers, Computational Systems Biology of Cancer, Clinical Translation, and Prevention and Early Detection.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Approval Process – Academic Research Proposed FY 2024 Cycle 1 RFAs

Dr. Le Beau introduced and provided an overview of five proposed FY2024 Cycle 1 (FY24.1) RFAs for Academic Research:

- Individual Investigator Research Awards
- Individual Investigator Research Awards for Computational Systems Biology of Cancer
- Individual Investigator Research Awards for Cancer in Children and Adolescents
- Individual Investigator Research Awards for Prevention and Early Detection
- Individual Investigator Research Awards for Clinical Translation

An Oversight Committee member commended Dr. Le Beau and CPRIT for funding research and researchers at institutions across Texas.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the five proposed FY 2024 RFAs presented by Dr. Le Beau.

Chief Prevention Officer Report and Grant Award Recommendations – Agenda Item 8, Tab 5

Presiding Officer Dr. Patel recognized Chief Prevention Officer Ramona Magid to present the prevention program report and award recommendations.

Ms. Magid provided an overview of the eight Prevention awards totaling \$13,577,257 recommended by the Program Integration Committee for FY 2023 review cycle 1. Ms. Magid reported that all applications address one or more of the Prevention Program priorities.

Recommended Prevention Program Awards FY 23.1

Grant ID	Mech	Application Title	PD	Organization	Score	Rank	Budget
PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si Cuenta!	Reininger, Belinda	The University of Texas Health Science Center at Houston	2.5	1	\$999,254
PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	2.7	2	\$2,500,000
PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta	The University of Texas Southwestern Medical Center	2.7	3	\$2,499,616
PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	3.0	4	\$449,959
PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	3.0	5	\$448,726
PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas	Savas, Lara	The University of Texas Health Science Center at Houston	3.1	6	\$2,499,492
PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	3.1	7	\$1,922,312
PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana	The University of Texas Medical Branch at Galveston	3.2	8	\$2,257,898

Primary Prevention of Cancer - PPC

Cancer Screening and Early Detection - CSD

Dissemination of CPRIT-Funded Cancer Control Interventions - DI

In response to an Oversight Committee member’s question, Ms. Magid confirmed that the HPV vaccination projects deliver services in public school systems.

An Oversight Committee member inquired about parental permission; Ms. Magid clarified that

HPV vaccinations require written parental consent.

Compliance Certification

Presiding Officer Dr. Patel reminded members that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member reported a conflict of interest with any of the proposed prevention awards.

Approval Process – Prevention Awards

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the PIC's eight recommendations for the following mechanisms: Cancer Screening and Early Detection, Dissemination of CPRIT-Funded Cancer Control Interventions; and Primary Prevention of Cancer.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Approval Process – Proposed Prevention RFAs for FY 2024 Cycle 1

Ms. Magid introduced and provided an overview of four proposed Prevention RFAs for FY 2024 Cycle 1:

- Dissemination of CPRIT- funded Cancer Prevention and Control Interventions
- Primary Prevention of Cancer
- Screening and Early Detection
- Colorectal Cancer Screening Coordinating Center

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the Prevention FY 2024 Cycle 1 proposed RFAs.

Chief Product Development Officer Report – Agenda Item 9, Tab 6

Presiding Officer Dr. Patel recognized Chief Product Development Officer Dr. Ken Smith to present the Product Development Research update.

Dr. Smith reported that the PDRC submitted their final six award recommendations for FY 2023 to the PIC and the Oversight Committee. However, because the requested project budgets recommended for funding exceed the total available funding for FY 2023 product development awards, he requested that the PIC defer action until the May meeting. With the additional time, he will negotiate the proposed budgets with each company. The goal is to reduce the requested project budgets to a total amount sufficient to fund all companies recommended for an award.

In response to a question by an Oversight Committee member regarding the timing and process for budget negotiations, Dr. Smith explained that he has communicated initially with the six companies and directed them to scrub their budgets. If CPRIT staff and the companies cannot reduce the budgets by an amount that will allow CPRIT to fund all six recommendations, then CPRIT will explore other options – including funding companies in the rank order until CPRIT depletes grant funds.

In response to a question by an Oversight Committee member inquiring about how the new preliminary application process was working for the program, Dr. Smith reported that the process worked well and that CPRIT will use the preliminary application process for the FY 2024 awards.

An Oversight Committee member asked whether the companies knew the PDRC's ranked order of companies recommended for funding. Dr. Smith responded that companies do not know their rank order.

An Oversight Committee member inquired regarding award caps and whether caps should be reinstated. Dr. Smith responded that he did not recommend reinstating a budget cap at this time. He noted that only two preliminary applications requested a budget that exceeded the previous \$20 million award cap, and neither application submitted a full application.

An Oversight Committee member asked about feedback from the companies on the FY 2023 review process. He also wanted to know the total time to approval if CPRIT acts on the proposed FY 2023 awards at the May meeting and how that compares to previous cycles. Dr. Smith explained that CPRIT is continually evaluating the review process for efficiency. The program has not yet received feedback from the companies.

An Oversight Committee member noted that he would like the program to reach out to county judges and economic development offices and request support from local municipalities. He feels that these offices should support CPRIT because CPRIT funds companies, and the local offices can assist with matching funds. Dr. Smith responded that this is an idea to investigate.

Dr. Smith briefly outlined his plans for the FY 2024 review cycle, including a more strenuous preliminary application review and expanding the pool of expert reviewers. He also explained that program staff will increase outreach regarding the Texas New Technologies Company and Texas Diagnostic and Devices Company RFAs.

Approval Process – Proposed Product Development RFAs for FY2024

Dr. Smith introduced the four proposed Product Development RFAs for FY 2024. He explained that the 2024 RFAs are the same as the FY 2023, with non-substantive changes:

- Texas Therapeutic Company
- Texas Device and Diagnostics Company
- Texas New Technologies Company
- Seed Company

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the four proposed FY 2024 RFAs presented by Dr. Smith.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11, Tab 8

Presiding Chair Dr. Patel took up agenda item 11 out of order and recognized Mr. Roberts to present his six appointments to the peer review panels.

Mr. Roberts presented his appointments to the CPRIT's Scientific Research and Prevention Programs Committee:

- Andrew Chow, M.D., Ph.D.
- Edward H. Cho, Ph.D.
- Eric J. Gomez, Ph.D.
- Holly K. Koblisch, Ph.D.
- Michael Hostetler, J.D., Ph.D.
- Sydney Xin-Li Lu, M.D., Ph.D.

MOTION:

On a motion by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the CEO's six appointments to the Scientific Research and Prevention Program Committee.

Advisory Committees – Item 12, Tab 9

Presiding Chair Dr. Patel recognized Mr. Roberts to present the Presiding Officer's new appointments to the advisory committees.

Mr. Roberts presented Dr. Atul Varadhachary's appointment to the Advisory Committee on Childhood Cancers and Harry Bushong's appointment to the Product Development Advisory Committee.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the two advisory committee appointments.

Academic Research Advisory Committee on Childhood Cancer presentation:

Presiding Officer Dr. Patel called on Dr. Le Beau to introduce Dr. Richard Gorlick, Chair of the Advisory Committee on Childhood Cancers (ACCC) to provide the ACCC annual report and recommendations.

Dr. Le Beau introduced Dr. Gorlick

Dr. Gorlick presented the ACCC annual report and recommendations.

Following Dr. Gorlick's report, an Oversight Committee member noted that the best care is usually close to home. Dr. Gorlick responded that large institutions in Texas are currently partnering with smaller rural institutions, and agreed that further expansion of these efforts was necessary.

Presiding Officer Dr. Patel and the Oversight Committee members thanked Dr. Gorlick for his presentation.

Prevention Advisory Committee Presentation:

Presiding Officer Dr. Patel called on Ms. Magid to introduce Dr. Navkiran Shokar, Chair of the Prevention Advisory Committee (PAC) and Ms. Sunceria Tillis, Vice Chair of the PAC.

Dr. Shokar and Ms. Tillis presented the PAC annual report and recommendations.

Dr. Shokar explained that the data reflected current projects (vs. historic data) in response to an Oversight Committee member's question.

In response to a question by an Oversight Committee member asking whether prevention project grantees collaborate with the private sector, Dr. Shokar mentioned several CPRIT-funded prevention projects have worked with private entities such as for-profit hospitals.

An Oversight Committee member about working with health plans for population health issues. Dr. Shokar responded that working with both the insured and uninsured populations is important to make an impact.

In response to an Oversight Committee member's question about Texas Cancer Registry data, Dr. Shokar explained that the registry provides excellent data on cancer incidence and mortality but does not collect the additional data that the PAC recommends CPRIT receive.

In response to a question by the Oversight Committee chair inquiring how long it would take to operationalize the recommendations, Dr. Shokar clarified that this was a long-term plan and

needs to be one that the PAC maintains and documents.

Presiding Officer Dr. Patel and the Oversight Committee members thanked Dr. Shokar and Ms. Tillis for the presentation.

Chief Operating Officer Report – Agenda Item 13, Tab 10

Presiding Chair Dr. Patel recognized Chief Operating Officer Heidi McConnell.

Ms. McConnell presented her report on the operating budget, performance measures, and debt issuance history located behind Tab 10. She updated members on the amount of revenue sharing payments from grantees, including a milestone payment of more than \$1 million and a quarterly royalty payment from Merck. She also notified members that CPRIT completed a “soft release” of the 2023 CPRIT Innovations VI Conference website earlier in February.

In response to a question by an Oversight Committee member, Ms. McConnell explained CPRIT expects 700-800 attendees will register for the conference.

Communication Report – Agenda Item 14, Tab 11

Presiding Officer Dr. Patel recognized Communications Director Mark Loeffler to present his report. Mr. Loeffler updated the committee members on communications activities.

Internal Auditor Report – Agenda Item 10, Tab 7

Returning to Agenda Item 10, Presiding Chair Dr. Patel recognized Mr. Graves to present the internal auditor report. He noted that at the conclusion of Mr. Graves report, the Oversight Committee would convene in closed session to receive an update on the Internal Audit Report over Information Technology General Controls.

Mr. Graves provided a status update on the fiscal year 2023 Internal Audit Plan and Schedule. He directed members to the Table of Summary Findings by year on pages 7-3 and 7-4.

There were no questions for Mr. Graves.

Presiding Chair Dr. Patel announced the committee would go into closed session at 11:49 a.m. pursuant to Texas Government Code § 551.076. He asked for Mr. Roberts, Ms. Doyle, Ms. McConnell, Mr. Burgess, Cameron Eckel, Shannon Cusick, Soma Emenike and Mr. Graves to join the members in closed session.

Presiding Officer Dr. Patel noted that upon return from closed session, the Oversight Committee would take up agenda items 18-19.

The Board reconvened in open session at 12:45 p.m.

Presiding Officer Dr. Patel announced that the Oversight Committee would not take up standing agenda items 15, 16 and 17.

Future Meeting Dates and Agenda Items – Agenda Item 18

Presiding Officer Dr. Patel reminded members that the CPRIT Oversight Committee will meet on May 17, 2023.


Adjournment – Agenda Item 19

Before adjournment, Mr. Roberts thanked Melanie Richardson and the CPRIT IT team for preparing the room for the first Oversight Committee meeting held in the Barbara Jordan building.

MOTION:

There being no further business, the Oversight Committee voted unanimously to approve Presiding Chair Dr. Patel’s motion to adjourn, which Dr. Hernandez seconded.

Meeting adjourned at 12:46 p.m.



Signature
Cindy Barberis Payne

5/17/23

Date
5/17/2023



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

WR
Cindy Barberio Payne

February 3, 2023

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 48 grant applications totaling \$90,711,335. The PIC recommendations for 40 academic research and eight prevention grant awards are attached.

Additionally at their February 1 meeting, the PIC unanimously deferred 25 academic research and six product development research award recommendations. To read the explanation for deferral and see the list of deferred applications, please refer to the separate letter provided to Oversight Committee members on the portal.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, and Ramona Magid, CPRIT's Chief Prevention Officer, have prepared overviews of the recommended academic research and prevention research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on February 15, 2023. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Le Beau, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

WRD
Cindy Barbato Payne

ACADEMIC RESEARCH GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of 40 academic research grant proposals totaling \$77,134,078. The recommended grant proposals were submitted in response to the following grant mechanisms: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; Texas Regional Excellence in Cancer Award (TREC); Recruitment of Established Investigators; and Recruitment of First-Time, Tenure-Track Faculty Members (RFT).*

The Scientific Review Council (SRC) provided the prioritized list of 65 recommendations for grant awards to the presiding officers on January 17, 2023. Upon recommendation from CPRIT’s Chief Scientific Officer, the PIC deferred 25 applications recommended by the SRC and recommended the remaining 40 to the Oversight Committee. The list of deferred applications can be found in the separate letter provided to Oversight Committee members.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

	IIRA	IIRA-CCA	IIRA-CSBC	IIRA-CT	IIRAP	TREC	REI	RFTFM
Statutory Funding Priority	<i>IIRA: Individual Investigator Research Awards; IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents; IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer; IIRACT: Individual Investigator Research Awards for Clinical Translation; IIRAP: Individual Investigator Research Awards for Prevention and Early Detection; TREC: Texas Regional Excellence in Cancer Award (TREC); REI: Recruitment of Established Investigators; RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;	✓	✓	✓	✓	✓	✓	✓	✓
Strengthen and enhance fundamental science in cancer research;	✓	✓	✓	✓	✓	✓	✓	✓
Ensure a comprehensive coordinated approach to cancer research;	✓	✓	✓	✓	✓	✓	✓	✓
Are interdisciplinary or interinstitutional;	✓	✓	✓	✓	✓	✓		
Address federal or other major research sponsors' priorities in	✓	✓	✓	✓	✓	✓	✓	✓

Statutory Funding Priority	IIRA	IIRA-CCA	IIRA-CSBC	IIRA-CT	IIRAP	TREC	REI	RFTFM
	<i>IIRA: Individual Investigator Research Awards; IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents; IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer; IIRACT: Individual Investigator Research Awards for Clinical Translation; IIRAP: Individual Investigator Research Awards for Prevention and Early Detection; TREC: Texas Regional Excellence in Cancer Award (TREC); REI: Recruitment of Established Investigators; RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
emerging scientific or technology Fields in the area of cancer prevention or cures for cancer;								
Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;	✓	✓	✓	✓	✓	✓		
Are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state	✓	✓	✓	✓	✓	✓		
Have a demonstrable economic development benefit to this stat	✓	✓	✓	✓	✓	✓	✓	✓
Enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources	✓	✓	✓	✓	✓	✓	✓	✓
Expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities						✓		
Address the goals of the Texas Cancer Plan	✓	✓	✓	✓	✓	✓	✓	✓

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACCSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
1	RP230026	IIRACCA	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407	1.0
2	RP230036	IIRAP	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196	1.0
3	RP230222	IIRA	Personalized Auricular Point Acupressure to Self- Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680	1.1
4	RP230140	IIRA	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000	1.1
5	RP230093	IIRA	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	1.8
6	RP230018	IIRACCA	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730	1.9

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
			Radiation Induced Cognitive Dysfunction				
7	RP230117	IIRAP	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330	1.9
8	RP230072	IIRA	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	1.9
9	RP230360	IIRA	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128	1.9
10	RP230135	IIRA	Blocking DNA Damage Response Induction of “Don’t Eat Me” Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905	2.0
11	RP230344	IIRA	Development and Evaluation of Lanosterol	McBayer, Samuel	The University of Texas Southwestern	\$1,048,465	2.0

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
			Synthase Inhibitors in Preclinical GBM Models		Medical Center		
12	RP230109	IIRA	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994	2.0
13	RP230373	IIRA	Immune Recognition in Pancreatic Cancer	Viale, Andrea	The University of Texas M.D. Anderson Cancer Center	\$1,049,985	2.0
14	RP230224	IIRA	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M.D. Anderson Cancer Center	\$1,049,997	2.0
15	RP230382	IIRA	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641	2.0
16	RP230247	IIRA	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	2.0
17	RP230063	IIRAP	Whole-Genome DNA Methylation Markers for Tracking and	Tsai, Robert	Texas A&M University System Health Science	\$2,000,000	2.1

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
			Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD		Center		
18	RP230285	IIRACT	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000	2.2
19	RP230160	IIRACSBC	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola, Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623	2.2
20	RP230334	IIRA	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000	2.5
21	RP230120	IIRACCA	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinom Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733	2.5

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
22	RP230213	IIRAP	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211	2.6
23	RP230363	IIRACSBC	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997	2.6
24	RP230391	IIRA	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000	2.6
25	RP230345	IIRA	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000	2.6
26	RP230166	IIRACSBC	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994	2.6

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
27	RP230154	IIRACCA	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000	2.6
28	RP230271	IIRA	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson Cancer Center	\$1,019,997	2.7
29	RP230330	IIRACCA	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815	2.7
30	RP230050	IIRA	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854	2.7
31	RP230261	IIRA	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997	2.7

Academic Research Award Recommendations						
<i>Cycle 23.1 Texas Regional Excellence in Cancer Award (TREC)</i>						
Rank	App. ID	Title	PI	Organization	Budget	Final Score
1	RP230419	South Texas Center of Excellence in Cancer Research (STCECR)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	\$6,000,000	2.8
2	RP230420	Impacting Cancer Outcomes in Hispanics (ICOHN)	LAKSHMANASWAMY, RAJKUMAR	Texas Tech University Health Sciences Center at El Paso	\$6,000,000	2.8
3	RP230204	Gene-Environment: Lifestyle Interactions in Cancer	Ramos, Kenneth	Texas A&M University System Health Science Center	\$5,998,422	2.8

Academic Research Recruitment Award Recommendations						
Cycles 23.2 – 23.3						
<i>REI: Recruitment of Established Investigators</i>						
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>						
Rank	App. ID	Mechanism	Candidate	Organization	Budget	Final Score
1	RR230012	RFTFM	Kenneth Hu, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
2	RR230017	RFTFM	Joe Nassour, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.5
3	RR230019	RFTFM	Lu Wang, Ph.D.	The University of Texas Health Science Center at San Antonio	\$2,000,000	1.6
4	RR230020	REI	Hongfang Liu, Ph.D.	The University of Texas Health Science Center at Houston	\$6,000,000	2.0
5	RR230018	REI	Rudi Fasan, Ph.D.	The University of Texas at Dallas	\$6,000,000	2.7
6	RR230015	RFTFM	Ewan McRae, Ph.D.	The Methodist Hospital Research Institute	\$1,999,977	2.8

PREVENTION GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of eight prevention grant proposals totaling \$13,577,257. The recommended grant proposals were submitted in response to the *Cancer Screening and Early Detection; Dissemination of CPRIT-Funded Cancer Control Interventions;* and *Primary Prevention of Cancer* grant mechanisms. The Prevention Review Council (PRC) provided the prioritized list of the recommendation for the award to the presiding officers on January 18, 2023. The PIC approved the award recommendations as presented by the PRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these prevention proposals met the following CPRIT funding priorities:

- Strengthen and enhance fundamental science in cancer research;
- Ensure a comprehensive coordinated approach to cancer research;
- Are interdisciplinary or interinstitutional;
- Have a demonstrable economic development benefit to this state; and
- Address the goals of the Texas Cancer Plan

Prevention Award Recommendations							
<i>CSD: Cancer Screening and Early Detection</i>							
<i>DI: Dissemination of CPRIT-Funded Cancer Control Interventions</i>							
<i>PPC: Primary Prevention of Cancer</i>							
Rank	App. ID	Mechanism	Application Title	PD	Organization	Budget	Final Score
1	PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si Cuenta!	Reininger, Belinda	The University of Texas Health Science Center at Houston	\$999,254	2.5
2	PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$2,500,000	2.7

Prevention Award Recommendations							
<i>CSD: Cancer Screening and Early Detection</i>							
<i>DI: Dissemination of CPRIT-Funded Cancer Control Interventions</i>							
<i>PPC: Primary Prevention of Cancer</i>							
Rank	App. ID	Mechanism	Application Title	PD	Organization	Budget	Final Score
3	PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	\$2,499,616	2.7
4	PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	\$449,959	3.0
5	PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	\$448,726	3.0
6	PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	\$2,499,492	3.1
7	PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an	Gerber, David E	The University of Texas Southwestern Medical Center	\$1,922,312	3.1

Prevention Award Recommendations							
<i>CSD: Cancer Screening and Early Detection</i>							
<i>DI: Dissemination of CPRIT-Funded Cancer Control Interventions</i>							
<i>PPC: Primary Prevention of Cancer</i>							
Rank	App. ID	Mechanism	Application Title	PD	Organization	Budget	Final Score
			urban safety-net system				
8	PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	\$2,257,898	3.2